The Major Histocompatibility Complex (MHC) is a genomic region in chromosome 6 which has been consistently found to be associated with the risk of developing virtually all common autoimmune diseases. Although its importance in disease pathogenesis has been known for decades, efforts to disentangle the roles of the classical human leukocyte antigens (HLA) and other variants responsible for the susceptibility to disease have often met with limited success, owing to the complex structure and extreme heterogeneity of the region. In this thesis, I interrogate the MHC for association with three common autoimmune diseases, ankylosing spondylitis, psoriasis and multiple sclerosis, with the aim of confirming the previously-reported associations and of identifying novel ones. To do so, I employ a systematic, joint analysis of single nucleotide polymorphism (SNP) and HLA allele data, in a logistic regression framework, using a recently developed algorithm to predict the HLA alleles for samples where such information is unavailable. To ensure the reliability of the analysis, I apply stringent quality control procedures and integrate over the uncertainty of the HLA allele predictions. Moreover, I resolve the haplotype phase of individuals from the HapMap project to create reliable reference panels, used in both HLA prediction and in quality control procedures. By directly testing HLA subtypes for association with the disease, the power to detect such associations is increased. I present the results of the analysis on the three disease phenotypes and discuss the evidence for important novel findings amongst both SNPs and HLA alleles in two of the diseases. In the final part of this thesis, I introduce a novel, model-based approach to detect inconsistencies in the data and show how it can be used to flag problematic SNPs which conventional quality control procedures may fail to identify.

O Fator de Necrose Tumoral-alfa (TNF-alfa) possui um importante papel na imunopatogênese da psoríase e agentes biológicos, como os inibidores de TNF-alfa, têm apresentado bons resultados no tratamento desta. No entanto, estes agentes foram associados ao aumento de casos de reativação de tuberculose entre os pacientes que os utilizaram. Este estudo foi realizado com o intuito de avaliar a resposta imune de pacientes com psoríase grave, ativa, sem tratamento, frente a antígenos de Mycobacterium tuberculosis (Mtb), e o efeito dos inibidores de TNF-alfa nesta resposta. Estudamos 24 pacientes com psoríase grave divididos em 2 grupos: não reatores (n = 14) e reatores (n = 10) ao teste intradérmico com PPD. Como controle, utilizamos um total de 26 indivíduos sadios, também separados em 2 grupos segundo a reatividade ao PPD (PPD-, n = 13; PPD+, n = 13). Em uma segunda etapa estudamos 11 pacientes com psoríase leve a moderada, também sem tratamento, PPD (-) para avaliarmos a importância da gravidade da psoríase na resposta aos antígenos micobacterianos. Avaliamos a resposta imunológica in vitro através da linfoproliferação, quantificação da produção de IFN-gama (ELISA) e quantificação de células produtoras de IFN-gama (ELISPOT), na presença e ausência dos inibidores de TNF-alfa (infliximab e etanercepte), utilizando os antígenos purificados ESAT-6, Ag85B e o antígeno bruto sonicado da cepa H37Rv (AgSMtb), e o mitógeno fitohemaglutinina (PHA). Os pacientes com psoríase grave PPD (-) apresentaram reposta linfoproliferativa e níveis de IFN-gama menores que nos controles PPD (-). Os pacientes com psoríase leve a moderada apresentaram resposta imune intermediária entre controles e pacientes graves. Em relação aos inibidores de TNF- alfa, verificou-se que infliximab e etanercepte apresentaram diferença em suas capacidades de inibição, sendo que somente o infliximab ocasionou a inibição total de TNF-alfa. Em contrapartida o etanercept manteve a produção de TNF-alfa, e em alguns casos elevou sua produção. Estes diminuíram apenas parcialmente a reatividade in vitro dos pacientes com psoríase, uma vez que a secreção de IFN-gama e o número de células produtoras de IFN-gama não foram alterados na presença dos inibidores. A secreção de IL-10 foi diminuída tanto na presença do infliximab, quanto na presença do etanercepte. Os dados obtidos permitem concluir que (a) os pacientes com psoríase grave PPD (-) apresentam uma baixa reatividade in vitro, principalmente das respostas que avaliam linfócitos T de memória central, aos antígenos de Mtb, sendo que essa baixa reatividade não está totalmente relacionada com a gravidade da doença, uma vez que os pacientes com psoríase leve a moderada apresentaram resposta intermediária a dos controles e pacientes com psoríase grave; (b) e que apesar dos inibidores de TNF- alfa promoverem uma inibição parcial da resposta imune, a reativação da tuberculose estaria mais relacionada à própria ausência de TNF-alfa, não compensada pela atuação isolada, e provavelmente insuficiente, de IFN-gama na manutenção do granuloma, do que a outras substanciais modificações na resposta imunológica frente aos antígenos micobacterianos. / Tumor necrosis factor alpha (TNF-alpha) has a pivotal role in psoriasis pathogenesis and biologic agents, such as TNF-alpha inhibitors, have provided good results in its treatment. However, the use of these agents has been associated with an increase in the number of cases of tuberculosis reactivation. This study aimed to evaluate the immune response of severe psoriasis patients, with active, untreated disease to relevant Mycobcterium tuberculosis antigens, and the effect of the TNF-alpha inhibitors (infliximab and etanercept) in this response. Twenty four severe psoriasis patients were enrolled and divided in two groups according to their reactivity to the tuberculin skin test: TST (n= 14) and TST + (n=10). As controls, we studied 26 healthy donors, also divided in two groups to the TST reactivity (TST -, n=13; TST+, n=13). Eleven mild to moderate psoriasis patients, untreated, TST (-) were studied to evaluated the role of psoriasis severity in the immune response to the mycobacterial antigens. Immune responses were evaluated in vitro by the lymphocyte proliferative response (LPR) assay, ELISA for IFN-? secretion by peripheral blood mononuclear cells and enumeration of IFN-? secreted cells (ELISPOT) induced in response to the purified antigens ESAT-6, Ag85B and a crude sonicated antigen preparation from H37Rv Mtb strain (AgSMtb), as well as to the mitogen phytohemagglutinin (PHA), in the presence or absenceinflimab/etanercept. The LPR and IFN-g secretion to Mtb antigens were lower in TST- severe psoriasis patients than TST- controls. Mild to moderate psoriasis patients had intermediate responses, between controls and severe psoriasis patients. The TNF-a inhibitors infliximab and etanercept showed differences in their inhibitiory activity, since only infliximab was capable to neutralize all TNF-a. On the other hand, etanercept kept TNF-alpha production, and in some cases even increased its production. The TNF-alpha inhibitors diminished partially the in vitro patients immune responses, since the IFN-? secretion and enumeration of IFN-? secreted cells were not affected. IL-10 secretion was diminished with both TNF-a inhibitors. In conclusion: (a) TST(-) severe psoriasis patients have decreased in vitro reactivity, mainly in those responses that evaluate central memory T-cell responses, to Mtb antigens, and this decrease could not be fully explained by disease severity, since mild psotiasis patients had intermediate responses; (b) and despite the fact that TNF-alpha inhibitors promote a partial immune response inhibition, tuberculosis reactivation could be related more with the lack of TNF-alpha, which was probably not compensated by the IFN-g activity alone, probably insufficient, to the support granuloma formation, than other defects of the immune response to Mtb antigens.

INTRODUÇÃO: A psoríase é doença inflamatória hiperproliferativa da pele, na qual mecanismos imunológicos são cruciais para o processo patogênico. O marcador CD57 denota inabilidade de replicação e imuno-senescência de células T CD8+, e sua expressão foi demonstrada em diversas condições inflamatórias. CD57 também pode ser expresso por células natural killer (NK), nas quais é considerado marcador de maturidade, por ser em geral adquirido pelas formas mais diferenciadas CD56+CD16+. A expressão de CD57 e outros receptores de células NK não foi amplamente investigada na psoríase. OBJETIVOS: Este estudo buscou examinar o fenótipo de células NK em biópsias de pele e células mononucleares do sangue periférico (CMSP) de pacientes com psoríase em relação a controles sadios. Este estudo investigou também o fenótipo e características funcionais de células T isoladas da pele lesional e não afetada de pacientes com psoríase. MÉTODOS: Foram isoladas células NK dos subtipos CD56+CD16- e CD56+CD16+ de pele lesional, não afetada e CMSP de pacientes com psoríase, comparadas com pele normal e CMSP de controles sadios. A expressão de CD57, NKG2A e NKG2C foi determinada nesses subtipos de células por citometria de fluxo. Células T CD4+ e CD8+ foram isoladas da pele lesional e não afetada de pacientes com psoríase, e a expressão de CD57 foi avaliada. Características funcionais de células T foram estudadas através da análise da secreção de diversas citocinas inflamatórias (IL-17A, IFN-\", IL-2, IL-33, TNF- #, IL-21, IL-22 and IL-27) produzidas por células T CD4+ e CD8+ isoladas por sorting celular, a partir de amostras de pele lesional e não afetada de pacientes com psoríase. RESULTADOS: Células NK isoladas das lesões de psoríase apresentaram um fenótipo particular, caracterizado por baixa expressão de CD57 e alta expressão de NKG2A na pele lesional e não afetada em relação aos controles. Em relação às células T, encontrouse frequência de células T CD4+CD57+ e CD8+CD57+ significativamente maior na pele não afetada em relação à pele lesional de pacientes com psoríase. Células T CD4+ isoladas por sorting celular a partir de amostras de pele lesional produziram níveis maiores de IL-17A, IL-22 e IFN-\" em relação às amostras de pele não afetada. Células T CD8+ isoladas da pele lesional secretaram maiores níveis de IL-17A, IFN-\", TNF-# e IL- 2 em relação à pele não afetada. CONCLUSÕES: Esses dados sugerem que células NK presentes nas lesões de psoríase apresentam fenótipo imaturo, que foi previamente associado a maiores capacidades funcionais, e poderiam ser implicadas na patogênese da psoríase. Em relação às células T, as características fenotípicas sugerem menor sobrevivência de células com baixa capacidade replicativa na pele lesional, pelo ambiente inflamatório local ou pelo alto turnover celular da psoríase / INTRODUCTION: Psoriasis is a hyper-proliferative inflammatory disease of the skin in which immunological mechanisms play a direct role in disease pathogenesis. CD57 is a marker of replicative inability and immunosenescence on CD8+ T cells and its expression is increased in a number of inflammatory conditions. CD57 is also expressed by NK cells and is considered a marker of NK cell maturity, being acquired by more differentiated CD56+CD16+ NK cells. The expression of CD57 and other NK cell markers in psoriasis has not been thoroughly investigated. OBJECTIVES: This study sought to examine the phenotype of NK cells in skin biopsies and peripheral blood mononuclear cells (PBMC) from patients with psoriasis and healthy controls. We also investigated the phenotype and functional characteristics of T cells from psoriasis patients, comparing lesional and unaffected skin. METHODS: CD56+CD16- and CD56+CD16+ NK cells were isolated from lesional skin, unaffected skin and PBMC of psoriasis patients, and normal skin and PBMC from healthy controls. The expression of CD57, NKG2A, and NKG2C was assessed by flow cytometry. CD57 expression was also determined on T cells from lesional and unaffected skin by flow cytometry. We assessed functional characteristics of T cells by evaluating the secretion of several inflammatory cytokines (IL-17A, IFN-\", IL- 2, IL-33, TNF-#, IL-21, IL-22 and IL-27), from cell-sorted purified CD4+ and CD8+ T cells isolated from lesional and unaffected skin of psoriasis patients, by multiplex assays. RESULTS: NK cells in psoriasis skin lesions exhibited a distinct phenotype, with CD57 expression significantly reduced and NKG2A expression increased on NK cells in lesional and unaffected skin compared to controls. In relation to T cells, we observed that the frequency of CD57+CD4+ and CD57+CD8+ T cells was significantly increased in unaffected skin of psoriasis patients compared to lesional skin. Sorted CD4+ T cells from psoriasis lesional skin produced higher levels of IL-17A, IL-22 and IFN-\" compared to unaffected skin. CD8+ T cells isolated from lesional skin produced higher levels of IL- 17A, IFN-\", TNF-# and IL-2 compared to unaffected skin. CONCLUSIONS: These data suggest that NK cells in psoriasis lesions exhibit an immature phenotype, that has been previously associated with higher functional abilities, and could implicate NK cells in psoriasis pathogenesis. For T cells, the findings of this study suggest lower survival of cells with low replicative ability in lesional skin, due to the local inflammatory environment or to the high cellular turnover in psoriasis

O tratamento de pacientes apresentando doenças inflamatórias imunomediadas com drogas anti-TNF-alfa aumenta o risco da reativação da tuberculose. Isso sugere que tais drogas possam afetar a imunidade celular destes. No entanto, há dados conflitantes sobre se esse tratamento suprime as respostas para o teste tuberculínico (TT) e os ensaios de liberação de interferon-gama (IGRAs) e poucos dados em pacientes com psoríase. O presente estudo avaliou pacientes com psoríase moderada a grave enfocando os efeitos do tratamento com infliximabe em suas respostas imunológicas celulares. Foram avaliadas as respostas imunes celulares de doze pacientes antes e durante o tratamento com infliximabe. As células mononucleares do sangue periférico (PBMC) foram estimuladas com a fito-hemaglutinina (PHA), o superantígeno enterotoxina B (SEB), um lisado de citomegalovírus (CMV), e antígenos de Mycobacterium tuberculosis, e a ativação de linfócitos foi avaliada por ELISPOT para enumerar células secretoras de IFN-y, por ELISA para detecção da secreção de IFN-y, e através da incorporação de[3H] timidina para medir a proliferação. O tratamento com infliximabe não levou à redução de INF-y e da resposta linfoproliferativa nos pacientes. Pelo contrário, aumentou a liberação desta citocina em culturas de PBMC estimulados com PHA e SEB por 12 h. Este efeito foi mais notado no pico do efeito clínico do agente anti-TNF (7 semanas de tratamento) e menos proeminente no seu nadir (logo antes da infusão da próxima dose). Reatividade imunitária ao CMV também não foi significativamente afetada, notando-se leve aumento pelo agente anti-TNF. É de se notar que secreção de IFN-y e resposta proliferativa a Mtb dos dois pacientes TT positivos foram, também, visivelmente aumentadas na semana 7, declinando quando infliximabe atingiu o seu nadir. Os efeitos deletérios do bloqueio do TNF em pacientes com psoríase grave, submetidos ao tratamento com infliximabe parecem ser atenuados, pelo menos parcialmente, por um efeito de aumento na imunidade mediada por células desses pacientes, possivelmente pela diminuição da ação imunossupressora decorrente do excesso de TNF / Treatment of patients with immune-mediated inflammatory diseases with anti-TNF agents increases the risk of tuberculosis reactivation, suggesting that it may affect their cellular immune response. However, there are conflicting data on whether anti-TNF treatment suppresses the responses to tuberculin skin test (TST) and interferon-y release assays and no information regarding psoriasis patients on anti-TNF treatment. The present study evaluated patients with moderate to severe psoriasis focusing on the effects of treatment with infliximab on their cellular immune responses. Cellular immune responses of twelve patients were evaluated before and during infliximab treatment. Peripheral blood mononuclear cells (PBMC) were stimulated with phytohemaglutinin (PHA), the superantigen enterotoxin B (SEB), a cytomegalovirus lysate (CMV), and Mycobacterium tuberculosis antigens, and the lymphocyte activation was evaluated by ELISPOT for enumeration of IFN-y-secreting cells, ELISA for detection of secreted IFN-y, and by [3H]thymidine incorporation for proliferation measurement. Treatment with infliximab does not lead to reduction in the INF-y and lymphoproliferative responses of patients. It rather increased the overnight release of this cytokine in PBMC cultures stimulated with PHA and SEB. This effect was most noted at the peak of the clinical effect of the anti-TNF agent (week 7 of treatment) and less prominent at its nadir (just before infusion of the next dose). Immune reactivity to CMV was also either unaffected or slightly increased by the TNF blocking agent. Of note, the IFN-y and proliferative responses to Mtb from the two TST-responder patients were also remarkably increased at week 7, declining when infliximab reached its nadir. The deleterious consequences of TNF blockade in patients with severe psoriasis undergoing infliximab treatment may be in part attenuated by an enhancing effect on the cell mediated immunity of the patients, possibly due to the abbreviation of the immunosuppressive effect of TNF overexpression

O prurido, assim como a dor, é uma experiência sensorial aversiva, associada ao desejo de coçar-se. Resultados prévios deste grupo demonstraram que a injeção i.d. de moléculas doadoras do sulfeto de hidrogênio (H2S), um novo mediador endógeno, reduziu o prurido agudo e a inflamação cutânea induzidos por histamina ou composto 48/80 (C48/80) na pele dorsal de camundongos, sugerindo o envolvimento do H2S no controle do prurido mediado por aminas. Todavia, pouco se conhece sobre os mecanismos envolvidos na indução ou inibição dessa percepção sensorial (aguda ou crônica), e a participação do H2S. A fim de aprofundar esse conhecimento, os objetivos deste estudo foram:i) testar e caracterizar os mecanismos envolvidos nos efeitos protetores de diferentes moléculas doadoras de H2S (liberação rápida e lenta) sobre o prurido agudo e inflamação associada, induzidos por estímulos dependente e independente de histamina, ii) averiguar a capacidade de produção endógena de H2S e as enzimas envolvidas em sua síntese na pele murina saudável e doente, iii) padronizar um modelo de prurido crônico associado ao escore de intensidade da área inflamada na psoríase (PASI), e investigar o efeito protetor de um doador de H2S de liberação lenta (GYY4137). Utilizando camundongos Balb/C, foi realizada a avaliação do comportamento de prurido agudo e inflamação cutânea (extravasamento plasmático, influxo de neutrófilos), frente a diversos estímulos, na ausência e vigência do co- tratamento (i.d.) com doadores de H2S. A psoríase experimental foi induzida pela aplicação tópica do creme imiquimode (IMQ 5%) na pele dorsal destes, por 5 dias consecutivos, e grupos paralelos com a doença foram tratados pela via intraperitoneal (i.p.) com o GYY4137 em diferentes doses (25-100 mg/kg). Os registros do prurido e PASI foram obtidos durante a indução da psoríase e as análises bioquímicas e moleculares foram realizadas ao término do experimento. O tratamento com doses crescentes de GYY4137 (0,3 30 nmol/sitio, i.d.) inibiu o prurido agudo induzido por histamina ou cloroquina e reduziu o influxo de neutrófilos frente ao C48/80, mas não afetou o extravasamento plasmático induzido por histamina ou C48/80. O bloqueio das enzimas geradoras de H2S maximizou o prurido e o influxo de neutrófilos desencadeado por C48/80. O pré-tratamento com a glibenclamida (10 mg/kg; i.p, -30 min), bloqueador dos canais de KATP, não reverteu o efeito do doador de H2S de liberação rápida sobre o prurido agudo e inflamação induzidos por histamina. Em animais com psoríase, o tratamento (i.p.) com o GYY4137 reduziu (P<0,05) a inflamação cutânea (escores PASI) e o prurido, assim como inibiu o eixo NF-<font face = \"symbol\">k B-caspase-1-IL-1<font face = \"symbol\">b , e aumentou a atividade das enzimas antioxidantes (catalase, GST, GR e GPx). A pele de animais com psoríase exibiu menor capacidade na síntese de H2S, que foi paralela à menor expressão da enzima Cistationina-<font face = \"symbol\">b-sintetase (CBS). O bloqueador da enzima Cistationina-<font face = \"symbol\">g-liase (CSE) não interferiu no escore PASI ou prurido. Conclui-se que moléculas doadoras de H2S representam novos alvos terapêuticos no controle da inflamação aguda ou imunomediada associada à percepção de prurido agudo ou crônico. No microambiente inflamatório agudo, o mecanismo envolvido é independente da ativação de canais de KATP, enquanto no crônico (psoríase) é dependente, em parte, da inibição da ativação do eixo NF-<font face = \"symbol\">k B- caspase-1-IL-1<font face = \"symbol\">b e aumento das defesas antioxidantes. / Pruritus, like pain, is an aversive sensory experience associated with the scratching desire. Previous findings from this group demonstrated that hydrogen sulphide (H2S) donor molecules, a new endogenous mediator, when intra-dermal injected, reduced acute histamine and cutaneous inflammation induced by histamine or compound 48/80 (C48/80) on the dorsal skin of mice, suggesting the involvement of H2S in the control of amine-mediated pruritus. However, little is known about the mechanisms involved in the induction or inhibition of this sensorial perception (acute or chronic) and the participation of H2S. In order to get a better understanding, the objectives of this study were: i) to test and characterize the mechanisms involved in the protective effects of different H2S donors molecules (fast and slow release) on acute pruritus and associated inflammation induced by histamine dependent and independent stimuli; ii) to investigate the endogenous production of H2S and the enzymes involved in its synthesis in healthy and unhealthy/disease murine skin; and iii) to standardize a model of chronic pruritus associated with the psoriasis area severity index (PASI) in the inflamed skin, and to investigate the protective effect of a slow release H2S donor (GYY4137). The behaviour evaluation of acute pruritus and cutaneous inflammation (plasma extravasation, neutrophil influx) was performed alongside with different stimuli with or without the co-treatment (i.d.) with H2S donors in Balb/C mice. Experimental psoriasis was induced by topical application of imiquimod cream (IMQ 5%) on the dorsal skin, for 5 consecutive days, and at the same time, groups with the disease were treated intraperitoneally (i.p.) with GYY4137 at different doses (25 100 mg/kg). Records of pruritus and PASI were obtained during psoriasis induction, and biochemical and molecular analyses were performed at the end of the experiment. Firstly, treatment with increasing doses of GYY4137 (0.3 30 nmol/site, i.d.) inhibited acute pruritus induced by histamine or chloroquine and reduced the neutrophils influx induced by C48/80, without affecting histamine or C48/80 plasma-induced extravasation. Secondly, blocking the H2S-generating enzymes potentiated pruritus and the neutrophils influx triggered by C48/80. Pretreatment with glibenclamide (10 mg/kg; i.p., -30 min.), a KATP channel blocker, did not reverse the effect of the fast-release H2S donor on acute pruritus and inflammation induced by histamine. Finally, psoriatic animals, treated with GYY4137 (i.p.) showed a lower skin inflammation (PASI scores) and pruritus as well as the NF<font face = \"symbol\">kB-Caspase1-IL-1<font face = \"symbol\">b axis inhibited (P>0.05), and increased activity of antioxidant enzymes (catalase, GST, GR and GPx). The skin of psoriatic animals exhibited a lower capacity to synthetize H2S, which was parallel to expression of the enzyme Cystathionine-<font face = \"symbol\">b-synthetase (CBS). The Cystathionine-<font face = \"symbol\">g-lyase (CSE) enzyme blocker did not interfere with the PASI or pruritus score. We may conclude that H2S donor molecules represent new therapeutic targets to the control of acute or immune- mediated inflammation associated with the perception of acute or chronic pruritus. Also, in the acute inflammatory microenvironment, the mechanism involved is independent of KATP channels activation, whereas in the chronic condition it is partly dependent on the inhibition of NF-<font face = \"symbol\">kB-caspase-1-IL-1<font face = \"symbol\">b axis activation and increased antioxidants defence.

O tratamento de pacientes apresentando doenças inflamatórias imunomediadas com drogas anti-TNF-alfa aumenta o risco da reativação da tuberculose. Isso sugere que tais drogas possam afetar a imunidade celular destes. No entanto, há dados conflitantes sobre se esse tratamento suprime as respostas para o teste tuberculínico (TT) e os ensaios de liberação de interferon-gama (IGRAs) e poucos dados em pacientes com psoríase. O presente estudo avaliou pacientes com psoríase moderada a grave enfocando os efeitos do tratamento com infliximabe em suas respostas imunológicas celulares. Foram avaliadas as respostas imunes celulares de doze pacientes antes e durante o tratamento com infliximabe. As células mononucleares do sangue periférico (PBMC) foram estimuladas com a fito-hemaglutinina (PHA), o superantígeno enterotoxina B (SEB), um lisado de citomegalovírus (CMV), e antígenos de Mycobacterium tuberculosis, e a ativação de linfócitos foi avaliada por ELISPOT para enumerar células secretoras de IFN-y, por ELISA para detecção da secreção de IFN-y, e através da incorporação de[3H] timidina para medir a proliferação. O tratamento com infliximabe não levou à redução de INF-y e da resposta linfoproliferativa nos pacientes. Pelo contrário, aumentou a liberação desta citocina em culturas de PBMC estimulados com PHA e SEB por 12 h. Este efeito foi mais notado no pico do efeito clínico do agente anti-TNF (7 semanas de tratamento) e menos proeminente no seu nadir (logo antes da infusão da próxima dose). Reatividade imunitária ao CMV também não foi significativamente afetada, notando-se leve aumento pelo agente anti-TNF. É de se notar que secreção de IFN-y e resposta proliferativa a Mtb dos dois pacientes TT positivos foram, também, visivelmente aumentadas na semana 7, declinando quando infliximabe atingiu o seu nadir. Os efeitos deletérios do bloqueio do TNF em pacientes com psoríase grave, submetidos ao tratamento com infliximabe parecem ser atenuados, pelo menos parcialmente, por um efeito de aumento na imunidade mediada por células desses pacientes, possivelmente pela diminuição da ação imunossupressora decorrente do excesso de TNF / Treatment of patients with immune-mediated inflammatory diseases with anti-TNF agents increases the risk of tuberculosis reactivation, suggesting that it may affect their cellular immune response. However, there are conflicting data on whether anti-TNF treatment suppresses the responses to tuberculin skin test (TST) and interferon-y release assays and no information regarding psoriasis patients on anti-TNF treatment. The present study evaluated patients with moderate to severe psoriasis focusing on the effects of treatment with infliximab on their cellular immune responses. Cellular immune responses of twelve patients were evaluated before and during infliximab treatment. Peripheral blood mononuclear cells (PBMC) were stimulated with phytohemaglutinin (PHA), the superantigen enterotoxin B (SEB), a cytomegalovirus lysate (CMV), and Mycobacterium tuberculosis antigens, and the lymphocyte activation was evaluated by ELISPOT for enumeration of IFN-y-secreting cells, ELISA for detection of secreted IFN-y, and by [3H]thymidine incorporation for proliferation measurement. Treatment with infliximab does not lead to reduction in the INF-y and lymphoproliferative responses of patients. It rather increased the overnight release of this cytokine in PBMC cultures stimulated with PHA and SEB. This effect was most noted at the peak of the clinical effect of the anti-TNF agent (week 7 of treatment) and less prominent at its nadir (just before infusion of the next dose). Immune reactivity to CMV was also either unaffected or slightly increased by the TNF blocking agent. Of note, the IFN-y and proliferative responses to Mtb from the two TST-responder patients were also remarkably increased at week 7, declining when infliximab reached its nadir. The deleterious consequences of TNF blockade in patients with severe psoriasis undergoing infliximab treatment may be in part attenuated by an enhancing effect on the cell mediated immunity of the patients, possibly due to the abbreviation of the immunosuppressive effect of TNF overexpression

O Fator de Necrose Tumoral-alfa (TNF-alfa) possui um importante papel na imunopatogênese da psoríase e agentes biológicos, como os inibidores de TNF-alfa, têm apresentado bons resultados no tratamento desta. No entanto, estes agentes foram associados ao aumento de casos de reativação de tuberculose entre os pacientes que os utilizaram. Este estudo foi realizado com o intuito de avaliar a resposta imune de pacientes com psoríase grave, ativa, sem tratamento, frente a antígenos de Mycobacterium tuberculosis (Mtb), e o efeito dos inibidores de TNF-alfa nesta resposta. Estudamos 24 pacientes com psoríase grave divididos em 2 grupos: não reatores (n = 14) e reatores (n = 10) ao teste intradérmico com PPD. Como controle, utilizamos um total de 26 indivíduos sadios, também separados em 2 grupos segundo a reatividade ao PPD (PPD-, n = 13; PPD+, n = 13). Em uma segunda etapa estudamos 11 pacientes com psoríase leve a moderada, também sem tratamento, PPD (-) para avaliarmos a importância da gravidade da psoríase na resposta aos antígenos micobacterianos. Avaliamos a resposta imunológica in vitro através da linfoproliferação, quantificação da produção de IFN-gama (ELISA) e quantificação de células produtoras de IFN-gama (ELISPOT), na presença e ausência dos inibidores de TNF-alfa (infliximab e etanercepte), utilizando os antígenos purificados ESAT-6, Ag85B e o antígeno bruto sonicado da cepa H37Rv (AgSMtb), e o mitógeno fitohemaglutinina (PHA). Os pacientes com psoríase grave PPD (-) apresentaram reposta linfoproliferativa e níveis de IFN-gama menores que nos controles PPD (-). Os pacientes com psoríase leve a moderada apresentaram resposta imune intermediária entre controles e pacientes graves. Em relação aos inibidores de TNF- alfa, verificou-se que infliximab e etanercepte apresentaram diferença em suas capacidades de inibição, sendo que somente o infliximab ocasionou a inibição total de TNF-alfa. Em contrapartida o etanercept manteve a produção de TNF-alfa, e em alguns casos elevou sua produção. Estes diminuíram apenas parcialmente a reatividade in vitro dos pacientes com psoríase, uma vez que a secreção de IFN-gama e o número de células produtoras de IFN-gama não foram alterados na presença dos inibidores. A secreção de IL-10 foi diminuída tanto na presença do infliximab, quanto na presença do etanercepte. Os dados obtidos permitem concluir que (a) os pacientes com psoríase grave PPD (-) apresentam uma baixa reatividade in vitro, principalmente das respostas que avaliam linfócitos T de memória central, aos antígenos de Mtb, sendo que essa baixa reatividade não está totalmente relacionada com a gravidade da doença, uma vez que os pacientes com psoríase leve a moderada apresentaram resposta intermediária a dos controles e pacientes com psoríase grave; (b) e que apesar dos inibidores de TNF- alfa promoverem uma inibição parcial da resposta imune, a reativação da tuberculose estaria mais relacionada à própria ausência de TNF-alfa, não compensada pela atuação isolada, e provavelmente insuficiente, de IFN-gama na manutenção do granuloma, do que a outras substanciais modificações na resposta imunológica frente aos antígenos micobacterianos. / Tumor necrosis factor alpha (TNF-alpha) has a pivotal role in psoriasis pathogenesis and biologic agents, such as TNF-alpha inhibitors, have provided good results in its treatment. However, the use of these agents has been associated with an increase in the number of cases of tuberculosis reactivation. This study aimed to evaluate the immune response of severe psoriasis patients, with active, untreated disease to relevant Mycobcterium tuberculosis antigens, and the effect of the TNF-alpha inhibitors (infliximab and etanercept) in this response. Twenty four severe psoriasis patients were enrolled and divided in two groups according to their reactivity to the tuberculin skin test: TST (n= 14) and TST + (n=10). As controls, we studied 26 healthy donors, also divided in two groups to the TST reactivity (TST -, n=13; TST+, n=13). Eleven mild to moderate psoriasis patients, untreated, TST (-) were studied to evaluated the role of psoriasis severity in the immune response to the mycobacterial antigens. Immune responses were evaluated in vitro by the lymphocyte proliferative response (LPR) assay, ELISA for IFN-? secretion by peripheral blood mononuclear cells and enumeration of IFN-? secreted cells (ELISPOT) induced in response to the purified antigens ESAT-6, Ag85B and a crude sonicated antigen preparation from H37Rv Mtb strain (AgSMtb), as well as to the mitogen phytohemagglutinin (PHA), in the presence or absenceinflimab/etanercept. The LPR and IFN-g secretion to Mtb antigens were lower in TST- severe psoriasis patients than TST- controls. Mild to moderate psoriasis patients had intermediate responses, between controls and severe psoriasis patients. The TNF-a inhibitors infliximab and etanercept showed differences in their inhibitiory activity, since only infliximab was capable to neutralize all TNF-a. On the other hand, etanercept kept TNF-alpha production, and in some cases even increased its production. The TNF-alpha inhibitors diminished partially the in vitro patients immune responses, since the IFN-? secretion and enumeration of IFN-? secreted cells were not affected. IL-10 secretion was diminished with both TNF-a inhibitors. In conclusion: (a) TST(-) severe psoriasis patients have decreased in vitro reactivity, mainly in those responses that evaluate central memory T-cell responses, to Mtb antigens, and this decrease could not be fully explained by disease severity, since mild psotiasis patients had intermediate responses; (b) and despite the fact that TNF-alpha inhibitors promote a partial immune response inhibition, tuberculosis reactivation could be related more with the lack of TNF-alpha, which was probably not compensated by the IFN-g activity alone, probably insufficient, to the support granuloma formation, than other defects of the immune response to Mtb antigens.

Background: According to current guidelines the cost of productivity loss should be considered in pharmacoeconomic analyses. The cost of health-related productivity loss in psoriasis patients is unknown. Objective: To estimate the cost of productivity loss in psoriasis and its association with health-related quality of life and clinical disease severity. Methods: Cross-sectional study, recruitment of adult participants through Internet advertisements. 201 (72.3%) out of 278 eligible participants completed the study. Health-related work productivity loss, quality of life and clinical severity of psoriasis were assessed by standardized instruments. Results: Indirect costs of productivity loss clearly exceed the total direct cost. In contrast to objective clinical disease severity, health-related quality of life (measured by the Dermatology Life Quality Index) is an independent predictor of work productivity. Conclusions: There is good reason to believe that intervention can reduce health-related productivity loss by improving patients’ quality of life. Savings from increased work productivity might offset comparatively high acquisition costs of biological agents. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

For elaborating my thesis I have chosen the topic: {\clqq}Psoriasis like stigma``. Taking into consideration that at present the public is interested in a number of diseases I would like more attention is paid to this stigmatized affection. I hold my interest in focusing my thesis on the stigmatization, because I know from clients with psoriasis that they really feel quite a number of problems in certain areas. My thesis is focused on two wholes, namely on theoretical and empirical parts. The first part of the theoretical part deals with problems of psoriasis, its forms, initiating mechanisms, manifestations and methods of treatment of this disease. The second part of the theoretical part deals with stigma, explanation of the concept stigma, what is the attitude of the society towards psoriatics, what is their position in their families, in work etc. In the empirical part my goal was to find out, whether the people with psoriasis are stigmatized and in which areas of life the psoriatics perceive their disease like stigma, whether they feel restricted in partnerships, working relationships and leisure time activities. Within a quantitative survey the data collection technique was applied {--} a questionnaire. The questionnaire was intended for the clients with psoriasis enlisted especially through the direct contact from the server www.lupenka.cz, further relatives, acquaintances and clients of Hospital České Budějovice. Overall 94 questionnaires were distributed. The questionnaire consisted of 34 questions concerning hypotheses. The clients with psoriasis introduced they feel restricted the most within the leisure time activities. In the empirical part I was gratified that the general nurses and physician have a great credit of psoriatics{\crq} awareness of their disease and help them to cope with the disease. I see the greatest problem in lack of information on psoriasis of the public. This disclosure leads to take a think of an improvement of the public awareness of this disease. As a proposal of this problem solution I propound to inform the public more so that the people get to know more information on psoriasis not only from physicians and nurses, but also from patients themselves being afflicted with the disease. The survey results can further serve as grounds for further study of the problems.

INTRODUÇÃO: A psoríase é doença inflamatória hiperproliferativa da pele, na qual mecanismos imunológicos são cruciais para o processo patogênico. O marcador CD57 denota inabilidade de replicação e imuno-senescência de células T CD8+, e sua expressão foi demonstrada em diversas condições inflamatórias. CD57 também pode ser expresso por células natural killer (NK), nas quais é considerado marcador de maturidade, por ser em geral adquirido pelas formas mais diferenciadas CD56+CD16+. A expressão de CD57 e outros receptores de células NK não foi amplamente investigada na psoríase. OBJETIVOS: Este estudo buscou examinar o fenótipo de células NK em biópsias de pele e células mononucleares do sangue periférico (CMSP) de pacientes com psoríase em relação a controles sadios. Este estudo investigou também o fenótipo e características funcionais de células T isoladas da pele lesional e não afetada de pacientes com psoríase. MÉTODOS: Foram isoladas células NK dos subtipos CD56+CD16- e CD56+CD16+ de pele lesional, não afetada e CMSP de pacientes com psoríase, comparadas com pele normal e CMSP de controles sadios. A expressão de CD57, NKG2A e NKG2C foi determinada nesses subtipos de células por citometria de fluxo. Células T CD4+ e CD8+ foram isoladas da pele lesional e não afetada de pacientes com psoríase, e a expressão de CD57 foi avaliada. Características funcionais de células T foram estudadas através da análise da secreção de diversas citocinas inflamatórias (IL-17A, IFN-\", IL-2, IL-33, TNF- #, IL-21, IL-22 and IL-27) produzidas por células T CD4+ e CD8+ isoladas por sorting celular, a partir de amostras de pele lesional e não afetada de pacientes com psoríase. RESULTADOS: Células NK isoladas das lesões de psoríase apresentaram um fenótipo particular, caracterizado por baixa expressão de CD57 e alta expressão de NKG2A na pele lesional e não afetada em relação aos controles. Em relação às células T, encontrouse frequência de células T CD4+CD57+ e CD8+CD57+ significativamente maior na pele não afetada em relação à pele lesional de pacientes com psoríase. Células T CD4+ isoladas por sorting celular a partir de amostras de pele lesional produziram níveis maiores de IL-17A, IL-22 e IFN-\" em relação às amostras de pele não afetada. Células T CD8+ isoladas da pele lesional secretaram maiores níveis de IL-17A, IFN-\", TNF-# e IL- 2 em relação à pele não afetada. CONCLUSÕES: Esses dados sugerem que células NK presentes nas lesões de psoríase apresentam fenótipo imaturo, que foi previamente associado a maiores capacidades funcionais, e poderiam ser implicadas na patogênese da psoríase. Em relação às células T, as características fenotípicas sugerem menor sobrevivência de células com baixa capacidade replicativa na pele lesional, pelo ambiente inflamatório local ou pelo alto turnover celular da psoríase / INTRODUCTION: Psoriasis is a hyper-proliferative inflammatory disease of the skin in which immunological mechanisms play a direct role in disease pathogenesis. CD57 is a marker of replicative inability and immunosenescence on CD8+ T cells and its expression is increased in a number of inflammatory conditions. CD57 is also expressed by NK cells and is considered a marker of NK cell maturity, being acquired by more differentiated CD56+CD16+ NK cells. The expression of CD57 and other NK cell markers in psoriasis has not been thoroughly investigated. OBJECTIVES: This study sought to examine the phenotype of NK cells in skin biopsies and peripheral blood mononuclear cells (PBMC) from patients with psoriasis and healthy controls. We also investigated the phenotype and functional characteristics of T cells from psoriasis patients, comparing lesional and unaffected skin. METHODS: CD56+CD16- and CD56+CD16+ NK cells were isolated from lesional skin, unaffected skin and PBMC of psoriasis patients, and normal skin and PBMC from healthy controls. The expression of CD57, NKG2A, and NKG2C was assessed by flow cytometry. CD57 expression was also determined on T cells from lesional and unaffected skin by flow cytometry. We assessed functional characteristics of T cells by evaluating the secretion of several inflammatory cytokines (IL-17A, IFN-\", IL- 2, IL-33, TNF-#, IL-21, IL-22 and IL-27), from cell-sorted purified CD4+ and CD8+ T cells isolated from lesional and unaffected skin of psoriasis patients, by multiplex assays. RESULTS: NK cells in psoriasis skin lesions exhibited a distinct phenotype, with CD57 expression significantly reduced and NKG2A expression increased on NK cells in lesional and unaffected skin compared to controls. In relation to T cells, we observed that the frequency of CD57+CD4+ and CD57+CD8+ T cells was significantly increased in unaffected skin of psoriasis patients compared to lesional skin. Sorted CD4+ T cells from psoriasis lesional skin produced higher levels of IL-17A, IL-22 and IFN-\" compared to unaffected skin. CD8+ T cells isolated from lesional skin produced higher levels of IL- 17A, IFN-\", TNF-# and IL-2 compared to unaffected skin. CONCLUSIONS: These data suggest that NK cells in psoriasis lesions exhibit an immature phenotype, that has been previously associated with higher functional abilities, and could implicate NK cells in psoriasis pathogenesis. For T cells, the findings of this study suggest lower survival of cells with low replicative ability in lesional skin, due to the local inflammatory environment or to the high cellular turnover in psoriasis